- Home
- CRT vs IVVD Comparison
CRT vs IVVD Comparison
Compare CRT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- IVVD
- Stock Information
- Founded
- CRT 1991
- IVVD 2020
- Country
- CRT United States
- IVVD United States
- Employees
- CRT N/A
- IVVD N/A
- Industry
- CRT Oil & Gas Production
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- IVVD Health Care
- Exchange
- CRT Nasdaq
- IVVD Nasdaq
- Market Cap
- CRT 65.1M
- IVVD 69.0M
- IPO Year
- CRT 1992
- IVVD 2021
- Fundamental
- Price
- CRT $9.78
- IVVD $0.72
- Analyst Decision
- CRT
- IVVD Strong Buy
- Analyst Count
- CRT 0
- IVVD 3
- Target Price
- CRT N/A
- IVVD $5.85
- AVG Volume (30 Days)
- CRT 24.7K
- IVVD 1.7M
- Earning Date
- CRT 01-01-0001
- IVVD 08-13-2025
- Dividend Yield
- CRT 9.01%
- IVVD N/A
- EPS Growth
- CRT N/A
- IVVD N/A
- EPS
- CRT 0.99
- IVVD N/A
- Revenue
- CRT $6,834,116.00
- IVVD $36,688,000.00
- Revenue This Year
- CRT N/A
- IVVD $446.60
- Revenue Next Year
- CRT N/A
- IVVD $112.63
- P/E Ratio
- CRT $9.89
- IVVD N/A
- Revenue Growth
- CRT N/A
- IVVD N/A
- 52 Week Low
- CRT $8.88
- IVVD $0.35
- 52 Week High
- CRT $13.31
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- CRT 43.47
- IVVD 43.88
- Support Level
- CRT $9.66
- IVVD $0.68
- Resistance Level
- CRT $9.88
- IVVD $0.82
- Average True Range (ATR)
- CRT 0.17
- IVVD 0.06
- MACD
- CRT 0.00
- IVVD -0.02
- Stochastic Oscillator
- CRT 16.44
- IVVD 11.07
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.